UCB’s Rystiggo Becomes Second FcRn Inhibitor Treatment For gMG

Following FDA Approval

 
• By Ayisha Sharma
  
blue light bulb in middle of row of white light bulbs against yellow background
Rystiggo Is The First Targeted Option For Patients With MuSK • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip